Beasley Allen Law Firm Files Motion for Sanctions against Merck in Vioxx Lawsuit

"Merck provided depositions of Mrs. Rogers and Dr. William Clancy, who treated her husband, to local and national press on April 12, in violation of the court's protective order. In fact, one reporter had the documents on this date apparently before it was even filed in court."

Beasley Allen rejects Mercks attempt to dismiss the First Vioxx Lawsuit

"Merck is thumbing it's nose at the justice system, and trying to pull a rabbit out of a hat by questioning the veracity of Cheryl Rogers whose husband, Howard, died at age 42 as a direct result of taking Vioxx."

Beasley Allen Says Bextra Recall May be Too Late for Thousands

Law firm Beasley Allen, lead counsel for the first Vioxx lawsuit set for May, believes that Pfizer's Bextra, a COX-2 inhibitor, posed a dual danger to thousands of consumers before its withdrawal last week.

Beasley Allen Law Firm Leads National COX-2 Litigation

One of the most popular in the COX-2 class, Vioxx - used by tens of millions of people worldwide - was pulled off the market last October. This decision came shortly after medical conference where FDA researcher David Graham showed higher doses of Vioxx correlated with a tripled risk of heart attack or sudden cardiac death compared to people who weren't taking any similar drug.

Beasley Allen Attorney Andy Birchfield Named Co-lead Counsel for Vioxx lawsuits

In a pretrial order issued today, Judge Fallon of the United States District Court in Louisiana appointed Mr. Birchfield of Beasley Allen as co-lead counsel with regard to pending Vioxx products liability litigation.

Beasley Allen Believes Bextra Recall was Long Overdue

Pfizer (the manufacturer of Celebrex and Bextra) suspended sales of their arthritis drug, Bextra, following a recommendation from the Food and Drug Administration (FDA). Unfortunately, this move may have come too late for thousands of people that have suffered a heart attack or stroke while taking this medication.

Beasley Allen Law Firm Calls Upon Pfizer for Celebrex Recall

"Our firm has been watching the situation unfold over the past 4 years. In light of the recent findings which undeniably link Celebrex to greater heart-attack risks, it is time for Pfizer to act responsibly and pull the drug from the market," said Mr. Methvin at a recent press conference.